Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    98 result(s) found for: Protein design. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-000562-36 Sponsor Protocol Number: BIG2-06/N063D/EGF106708 Start Date*: 2007-05-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb...
    Medical condition: Operable primary breast cancer with over expression/ amplification of HER2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003511-31 Sponsor Protocol Number: V99P2 Start Date*: 2008-07-16
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ In...
    Medical condition: no medical condition: healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002962-37 Sponsor Protocol Number: NA_00008675 Start Date*: 2010-09-14
    Sponsor Name:VU Medical Center Amsterdam
    Full Title: Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, ...
    Medical condition: Patients with metastatic or inoperable renal cell cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000545-40 Sponsor Protocol Number: FELZ01 Start Date*: 2021-08-01
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial
    Medical condition: Late active or chronic active antibody-mediated rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000631-92 Sponsor Protocol Number: CQGE031A2208 Start Date*: 2011-12-07
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and olde...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003371-34 Sponsor Protocol Number: CDI-CS-002 Start Date*: 2015-02-20
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma
    Medical condition: Advanced or recurrent solid tumors, recurrent or progressive glioblastoma, or high-grade glioma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001877-94 Sponsor Protocol Number: COX-2I Start Date*: 2012-09-17
    Sponsor Name:UNIVERSITY CLINIC GOLNIK
    Full Title: Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC)
    Medical condition: extensive disease small-cell lung cancer (ED-SCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000311-98 Sponsor Protocol Number: P2005V3 Start Date*: 2005-11-09
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa
    Medical condition: Chronic pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003451-38 Sponsor Protocol Number: OVG2018/05 Start Date*: 2019-02-21
    Sponsor Name:Clinical Trials and Research Governance (CTRG)
    Full Title: Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy.
    Medical condition: Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004070-22 Sponsor Protocol Number: CV-NCOV-003 Start Date*: 2021-04-12
    Sponsor Name:CureVac AG
    Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi...
    Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001937-40 Sponsor Protocol Number: EORTC 16032-18031 Start Date*: 2005-05-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma
    Medical condition: Unresectable and progressive metastatic cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027155 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001429-33 Sponsor Protocol Number: IM140-103 Start Date*: 2014-11-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP)
    Medical condition: Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003300-11 Sponsor Protocol Number: 105553 Start Date*: 2005-11-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococ...
    Medical condition: Three dose primary vaccination of healthy infants between 6 and 12 weeks of age at the time of the first vaccination against Streptococcus pneumaniae
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-001937-11 Sponsor Protocol Number: 132333 Start Date*: 2020-04-30
    Sponsor Name:University College London
    Full Title: A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised p...
    Medical condition: Respiratory illness caused by Covid-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001624-17 Sponsor Protocol Number: 210321 Start Date*: 2021-07-21
    Sponsor Name:Karolinska University Hospital
    Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog...
    Medical condition: Climacteric symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000837-17 Sponsor Protocol Number: NL80854.018.22 Start Date*: 2022-12-07
    Sponsor Name:Amsterdam UMC
    Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study
    Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004423-36 Sponsor Protocol Number: PTG-300-03 Start Date*: 2019-04-08
    Sponsor Name:Protagonist Therapeutics, Inc.
    Full Title: An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-thalassemia Subjects
    Medical condition: β-Thalassemia Subjects with Chronic Anemia (transfusion and non transfusion dependent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000824-32 Sponsor Protocol Number: IMDZ-04-1702 Start Date*: 2018-10-19
    Sponsor Name:Immune Design Corp.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Follo...
    Medical condition: Unresectable locally-advanced or metastatic synovial sarcoma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005327-16 Sponsor Protocol Number: Start Date*: 2014-07-15
    Sponsor Name:The University of Edinburgh [...]
    1. The University of Edinburgh
    2. NHS Lothian
    Full Title: A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery
    Medical condition: Post-operative pain
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002455-97 Sponsor Protocol Number: 13381 Start Date*: 2016-10-19
    Sponsor Name:University of Southampton
    Full Title: Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care
    Medical condition: Respiratory tract infections in children aged between 6 months and 12 years
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10066740 Acute respiratory tract infection LLT
    21.1 10021881 - Infections and infestations 10024968 Lower respiratory tract infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 02 14:16:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA